FDA regulation is already everywhere: FADE the narrative, hunt the sub-claims instead
The Opportunity
Direction is FADE because the edge is explicitly decaying: the upstream evidence mix contains Tier-1 domains and broad propagation, which means whatever the “FDA regulation” narrative is, it is already in the market’s bloodstream. Trading it as new information is structurally late. The only remaining opportunity is second-order: find a specific implementation detail that is not yet priced, not the generic theme.
The Timing
With a Bearish 78 regime, regulatory headlines can still move multiples, but this signal is already in propagation_monitor with a catalytic posture. That is the system telling you the timing window for “first discovery” is closed. Timing only re-opens if a new FDA artefact changes the rulebook or if a named company is hit with a discrete action tied to the broader theme.
The Evidence
Upstream explicitly states: lifecycle spreading, edge decaying, and the decision direction is FADE with rationale “edge closed; information has propagated to mainstream.” No direct tickers are provided in the 7A packet for expression. This is a narrative state, not a tradable event in this run.